RICERCA
AUTORI
RIVISTE
Sfoglia per RIVISTA
THE LANCET. HAEMATOLOGY
Collezione AOU Città della Salute di Torino
Items : 31
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X.
2025
AOU Città della Salute di Torino
Mina R; Mylin AK; Yokoyama H; Magen H; Alsdorf W; Minnema MC; Shune L; Isufi I; Harrison SJ; Shah UA; Schecter JM; Vogel M; Lendvai N; Gries KS; Katz EG; Slaughter A; Lonardi C; Gilbert J; Li Q; Deraedt W; Filho OC; Patel N; Florendo E; Karlin L; Weisel K;
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2024 Nov;11(11):e830-e838. doi: 10.1016/S2352-3026(24)00241-2. Epub 2024 Sep 20.
2024
AOU Città della Salute di Torino
Russo D; Polverelli N; Bernardi S; Santarone S; Farina M; Borlenghi E; Onida F; Castagna L; Bramanti S; Carella AM; Sorasio R; Martino M; Alati C; Olivieri A; Beltrami G; Curti A; Vetro C; Leotta S; Mancini V; Terruzzi E; Bernardi M; Galieni P; Musto P; Cerretti R; Giaccone L; Skert C; Radici V; Vezzoli M; Calza S; et alii...
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2024 Jul;11(7):e499-e509. doi: 10.1016/S2352-3026(24)00143-1.
2024
AOU Alessandria
AOU Città della Salute di Torino
Della Starza I; Drandi D; Genuardi E; Ciabatti E; Bomben R; De Novi LA; Cavalli M; Guarini A; Grapulin L; Assanto GM; Annechini G; Tani M; Celli M; Mannina D; Mannarella C; Cencini E; Re F; Bigliardi S; Corradini P; Stelitano C; Tucci A; Perrone T; Gaidano G; Musuraca G; Bernuzzi P; Bolis SA; Zilioli VR; Rattotti S; Ferreri AJM; et alii...
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1.
2023
AOU Città della Salute di Torino
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P;
10-day decitabine versus 3?+?7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9.
2023
AOU Città della Salute di Torino
AOU Novara
Becker H; Blijlevens N; Wäsch R; Vilque JP; Ammatuna E; Efficace F; de Graaf AO; Stevens-Kroef M; Jansen JH; Hoogendoorn M; Giraut A; Posthuma EFM; van Lammeren-Venema D; Gaidano G; Foà R; Legrand O; Candoni A; Audisio E; Fuhrmann S; Luppi M; Vrhovac R; Crysandt M; Neubauer A; Griškevi?ius L; Noppeney R; Van der Velden WJFM; Chantepie S; Kicinski M; Wijermans PW; et alii...
Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. in The Lancet. Haematology / Lancet Haematol. 2022 May;9(5):e361-e373. doi: 10.1016/S2352-3026(22)00073-4.
2022
AOU Città della Salute di Torino
Stemler J; de Jonge N; Skoetz N; Sinkó J; Brüggemann RJ; Busca A; Ben-Ami R; Rá?il Z; Piechotta V; Lewis R; Cornely OA;
An integrated approach to cardioprotection in lymphomas. in The Lancet. Haematology / Lancet Haematol. 2022 Jun;9(6):e445-e454. doi: 10.1016/S2352-3026(22)00082-5. Epub 2022 May 2.
2022
AOU Città della Salute di Torino
Maraldo MV; Levis M; Andreis A; Armenian S; Bates J; Brady J; Ghigo A; Lyon AR; Manisty C; Ricardi U; Aznar MC; Filippi AR;
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9.
2022
AOU Città della Salute di Torino
Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legie? W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špi?ka I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;
Antibody-drug conjugates: when chemotherapy meets immuno-oncology. in The Lancet. Haematology / Lancet Haematol. 2021 Nov;8(11):e778-e779. doi: 10.1016/S2352-3026(21)00236-2. Epub 2021 Sep 13.
2021
AOU Città della Salute di Torino
Mina R; Gay F;
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Mar;8(3):e175-e184. doi: 10.1016/S2352-3026(20)30373-2. Epub 2021 Jan 18.
2021
AOU Città della Salute di Torino
AOU Novara
Rambaldi A; Finazzi MC; Tognoni G; Bucelli C; Vianelli N; Bellini M; Scaffidi L; Lunghi F; Betti S; Guglielmelli P; Mannarelli C; Loscocco GG; Mora B; Cacciola E; Cascavilla N; Patriarca A; Siragusa S; Rumi E; Rapezzi D; Musolino C; Caramella M; Carli G; Benevolo G; Pane F; Ricco A; Palandri F; Iurlo A; Ciceri F; Bonifacio M; et alii...
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Jan;8(1):e34-e44. doi: 10.1016/S2352-3026(20)30358-6. Epub 2020 Dec 22.
2021
AOU Alessandria
AOU Città della Salute di Torino
Vitolo U; Martelli M; Stelitano C; Ciccone G; Narni F; Casaroli I; Stefani PM; Puccini B; Benedetti F; Ferreri AJM; Molinari AL; Ballerini F; Arcaini L; Gomes da Silva M; Chiappella A; Zilioli VR; Balzarotti M; Stefoni V; Pagani C; Re A; Di Rocco A; Zanni M; Cavallo F; Mian M; Tavarozzi R; Ferrero S; Evangelista A; Ladetto M; Cortelazzo S; et alii...
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5.
2021
AOU Città della Salute di Torino
AOU Novara
Liberati AM; Novak U; Osborne W; Frezzato M; Fox CP; Davies A; Cascavilla N; Bernardi M; Gastaldi E; Cozens K; Bromberg JEC; Singh V; Fanni A; Re F; Patti C; McKay P; Olivieri J; Linton K; Nassi L; Cellini C; Botto B; Cattaneo C; Khwaja J; Luppi M; Calimeri T; Doorduijn JK; Re A; Cabras MG; Smith J; et alii...
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. in The Lancet. Haematology / Lancet Haematol. 2021 Dec;8(12):e934-e946. doi: 10.1016/S2352-3026(21)00278-7. Epub 2021 Oct 28.
2021
AOU Città della Salute di Torino
Ludwig H; Sonneveld P; Facon T; San-Miguel J; Avet-Loiseau H; Mohty M; Mateos MV; Moreau P; Cavo M; Pawlyn C; Zweegman S; Engelhardt M; Driessen C; Cook G; Dimopoulos MA; Gay F; Einsele H; Delforge M; Caers J; Weisel K; Jackson G; Garderet L; van de Donk N; Leleu X; Goldschmidt H; Beksac M; Nijhof I; Schreder M; Abildgaard N; et alii...
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. in The Lancet. Haematology / Lancet Haematol. 2020 Sep;7(9):e649-e659. doi: 10.1016/S2352-3026(20)30208-8. Epub 2020 Aug 3.
2020
AOU Città della Salute di Torino
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V;
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. in The Lancet. Haematology / Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.
2020
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Corradini P; Pagano L; Bertù L; Corrao G; Grossi PA; Franchi M; Oberti M; Zappasodi P; Visco C; Armiento D; Pane F; Pinto A; Galieni P; Rigacci L; Candoni A; Venditti A; Fava C; Federici AB; Marchesi F; Musto P; Gentile M; Bocchia M; Di Renzo N; Olivieri A; Ferrandina C; Selleri C; Ortu La Barbera E; Luppi M; Scattolin AM; et alii...
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen? in The Lancet. Haematology / Lancet Haematol. 2020 May;7(5):e355-e357. doi: 10.1016/S2352-3026(19)30254-6. Epub 2020 Mar 11.
2020
AOU Città della Salute di Torino
Gay F; Mina R; D'Agostino M;
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. in The Lancet. Haematology / Lancet Haematol. 2020 May;7(5):e395-e407. doi: 10.1016/S2352-3026(20)30044-2. Epub 2020 Mar 23.
2020
AOU Città della Salute di Torino
Anderson K; Nordström E; Chauhan D; Byrne C; Zubair H; Paba-Prada C; Reeves B; Mellqvist UH; Plesner T; Voorhees P; Bringhen S; Richardson PG; Harmenberg J; Palumbo A; Sonneveld P;
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
2020
AOU Città della Salute di Torino
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; et alii...
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2020 Jan;7(1):e18-e27. doi: 10.1016/S2352-3026(19)30219-4. Epub 2019 Nov 5.
2020
AOU Città della Salute di Torino
Young G; Gauger CA; Massicotte MP; Kállay K; Peters M; Saracco P; Martinelli I; Biss TT; Beyer-Westendorf J; Lvova O; Yee DL; Bhat RV; Chalmers E; Simioni P; Amedro P; Santamaría A; Holzhauer S; Kenet G; Chan AKC; Hooimeijer HL; Torres M; Connor P; Bonnet D; Hege K; Nurmeev I; Kumar R; Palumbo JS; Male C; Lensing AWA; et alii...
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. in The Lancet. Haematology / Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.
2019
AOU Città della Salute di Torino
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. in The Lancet. Haematology / Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13.
2019
AOU Città della Salute di Torino
Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
Monoclonal antibody-drug conjugates in B-cell lymphomas. in The Lancet. Haematology / Lancet Haematol. 2019 May;6(5):e232-e233. doi: 10.1016/S2352-3026(19)30048-1. Epub 2019 Mar 29.
2019
AOU Città della Salute di Torino
Chiappella A; Vitolo U;
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. in The Lancet. Haematology / Lancet Haematol. 2019 May;6(5):e276-e284. doi: 10.1016/S2352-3026(19)30027-4.
2019
AOU Città della Salute di Torino
Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H;
Frailty in multiple myeloma: the need for harmony to prevent doing harm. in The Lancet. Haematology / Lancet Haematol. 2019 Mar;6(3):e117-e118. doi: 10.1016/S2352-3026(19)30011-0. Epub 2019 Feb 6.
2019
AOU Città della Salute di Torino
Zweegman S; Larocca A;
Histological transformation and secondary malignancies in follicular lymphoma. in The Lancet. Haematology / Lancet Haematol. 2018 Nov;5(11):e496-e497. doi: 10.1016/S2352-3026(18)30170-4.
2018
AOU Città della Salute di Torino
Vitolo U; Chiappella A; Vitolo U; Chiappella A;
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.
2017
AOU Città della Salute di Torino
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; et alii...
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. in The Lancet. Haematology / Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.
2017
AOU Città della Salute di Torino
Ladetto M; Pileri SA; Salvi F; Carella AM; Gotti M; Finotto S; Zambello R; Fabbri A; Pinotti G; Rocco AD; Tani M; Rigacci L; Molinari A; Spina M; Evangelista A; Barbero D; Ferrero S; Patti C; Nassi L; Chiappella A; Visco C; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U;
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. in The Lancet. Haematology / Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9.
2016
AOU Città della Salute di Torino
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Ma?kowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; et alii...
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. in The Lancet. Haematology / Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.
2016
AOU Città della Salute di Torino
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; et alii...
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. in The Lancet. Haematology / Lancet Haematol. 2016 Apr;3(4):e196-204. doi: 10.1016/S2352-3026(16)00021-1. Epub 2016 Mar 18.
2016
AOU Città della Salute di Torino
Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C;
Immunotherapy: the next step in the treatment of myeloma. in The Lancet. Haematology / Lancet Haematol. 2015 Dec;2(12):e504-5. doi: 10.1016/S2352-3026(15)00226-4. Epub 2015 Nov 16.
2015
AOU Città della Salute di Torino
Palumbo A;